Lidocaine Hydrochloride

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

Access all COS suppliers
Check all USDMF suppliers

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

50 API Suppliers, 13 USDMF, 9 CEP/COS, 3 JDMF, 10 EU WC, 13 KDMF, 30 NDC API, 37 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

4 Drugs in Development

4 Drugs in Development

FINISHED DOSAGE FORMULATIONS

409 FDF Dossiers, 226 FDA Orange Book, 67 Europe, 63 Canada, 17 South Africa, 36 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;INJECTION - 4%, INJECTABLE;INJECTION - 1% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INJECTION - 2% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INJECTION - 20% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INJECTION - 4% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INJECTION - 0.005MG/ML;0.5%, INJECTABLE;INJECTION - 0.005MG/ML;1%, INJECTABLE;INJECTION - 0.005MG/ML;1.5%, INJECTABLE;INJECTION - 0.005MG/ML;2%, INJECTABLE;INJECTION - 0.01MG/ML;1%, INJECTABLE;INJECTION - 0.01MG/ML;2%, INJECTABLE;INJECTION - 0.02MG/ML;2%, INJECTABLE;INJECTION - 0.5%, INJECTABLE;INJECTION - 1%, INJECTABLE;INJECTION - 1.5%, INJECTABLE;INJECTION - 2%, INJECTABLE;INJECTION - 1%, INJECTABLE;INJECTION - 2%, INJECTABLE;INJECTION - 1%, INJECTABLE;SPINAL - 5%, JELLY;TOPICAL - 2% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INJECTION - EQ 0.02MG BASE/ML;2%, INJECTABLE;INJECTION - EQ 0.01MG BASE/ML;2%

RELATED EXCIPIENT COMPANIES

6 Rochem International Inc, 12 SPI Pharma, 3 Seqens, 13 DKSH, 1 Jai Radhe Sales, 1 PMC Isochem, 1 Pharm-RX Chemical, 1 Boai NKY Pharmaceuticals Ltd, 8 Gangwal Healthcare, 19 Nanjing Well Pharmaceutical, 1 ACG Worldwide, 22 Actylis, 3 Aeon Procare, 4 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 43 BASF, 1 Bioplus Life Sciences, 1 BioSpectra, 1 Clariant, 17 Corel Pharma Chem, 3 Doshion Polyscience, 5 Finar, 13 Gangwal Chemicals, 4 Ideal Cures Pvt Ltd, 2 Ingredion Pharma Solutions, 18 Kerry, 4 Kima Chemical, 6 Lonza Capsugel, 9 Lubrizol Life Science Health, 9 Microlex e.U, 3 Nanjing Bold Chemical, 2 Nippon Fine Chemical, 2 Nomisma Healthcare, 2 Novo Excipients, 1 Pharmatrans-Sanaq, 4 Pluviaendo, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 21 Roquette, 25 Seppic, 3 Shandong Focus Biotechnology Co., Ltd, 3 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 4 Sigachi Industries, 3 The Dow Chemical Company, 1 Ulanqab Kema New Material, 2 Valens Pharmachem, 1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

75 Topical, 65 Solubilizers, 52 Coating Systems & Additives, 45 Thickeners and Stabilizers, 38 Fillers, Diluents & Binders, 35 Parenteral, 33 Controlled & Modified Release, 31 Emulsifying Agents, 26 Film Formers & Plasticizers, 25 Direct Compression, 23 Surfactant & Foaming Agents, 18 Co-Processed Excipients, 18 Granulation, 18 Taste Masking, 15 Rheology Modifiers, 10 Lubricants & Glidants, 10 API Stability Enhancers, 9 Disintegrants & Superdisintegrants, 8 Chewable & Orodispersible Aids, 5 Empty Capsules, 4 Vegetarian Capsules, 4 Coloring Agents, 1 Soft Gelatin

DIGITAL CONTENT

2 DATA COMPILATION #PharmaFlow, 60 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

3 US Medicaid Prescriptions, 59 Finished Drug Prices

MARKET PLACE

50 APIs, 15 FDF Dossiers

PATENTS & EXCLUSIVITIES

4 US Patents

4 US Patents

REF. STANDARDS & IMPURITIES

1 EDQM, 1 USP, 1 Others

Xls

Filters

Company Name

Year

DEALS // DEV.

Country

Sponsor

Therapeutic Area

Study Phase

Deal Type

Product Type

Dosage Form

Lead Product

Target

Filters

Reset Filter

All Developments

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

Reset All

01

Aspen Pharmacare Holdings

South Africa

PackExpo

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Lead Product(s) : Lidocaine Hydrochloride

Therapeutic Area : Neurology

Study Phase : Approved

Sponsor : Sandoz B2B

Deal Size : $440.0 million

Deal Type : Acquisition

DEALS_DEV

Sandoz completes acquisition of Aspen’s Japanese operations, strengthening its position in world’s third l...

Details : The acquisition strengthens Sandoz’s presence in the hospital channel by complementing the broad Sandoz portfolio and pipeline of hospital generic and biosimilar products in Japan like Lidocaine Hydrochloride.

Brand Name : Lidocaine HCl-Generic

Molecule Type : Small molecule

Upfront Cash : $330.0 million

January 31, 2020

Lead Product(s) : Lidocaine Hydrochloride

Therapeutic Area : Neurology

Highest Development Status : Approved

Sponsor : Sandoz B2B

Deal Size : $440.0 million

Deal Type : Acquisition

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

Virtual Booth

02

Eugia Pharma

India

2024 ACI Convention

Not Confirmed

03

Sustained Therapeutics

U.S.A

2024 ACI Convention

Not Confirmed

04

SINTETICA SA

Switzerland

2024 ACI Convention

Not Confirmed

05

Amneal Pharmaceuticals

U.S.A

2024 ACI Convention

Not Confirmed

Find Clinical Drug Pipeline Developments & Deals for Lidocaine Hydrochloride